表紙：C型肝炎治療薬の市場規模、シェア、成長分析：薬剤クラス別、投与経路別、疾患タイプ別、地域別 - 産業予測、2025～2032年

市場調査レポート

商品コード

1789216

C型肝炎治療薬の市場規模、シェア、成長分析：薬剤クラス別、投与経路別、疾患タイプ別、地域別 - 産業予測、2025～2032年

Hepatitis C Drugs Market Size, Share, and Growth Analysis, By Drug Class (direct acting antiviral (NS3/4A protease inhibitor, NS5A inhibitor)), By Routes of Administration (oral, injectable), By Disease Type, By Region - Industry Forecast 2025-2032

出版日: 2025年08月08日
発行: SkyQuest
ページ情報: 英文 198 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 787,898円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 921,692円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,055,486円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.66円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界のC型肝炎治療薬の市場規模は、2023年に125億米ドルと評価され、予測期間（2025～2032年）のCAGRは4.2％で成長し、2024年の130億2,000万米ドルから2032年には180億5,000万米ドルに成長すると予測されています。

世界のC型肝炎治療薬市場は、認知度の向上、診断の進歩、効果的な治療オプションに後押しされ、ダイナミックな成長を遂げています。C型肝炎の有病率の上昇は、特に高齢者など感染率の高い層における抗ウイルス療法の需要を促進しています。ウイルスの根絶を目指す政府やヘルスケア機関の取り組みは、市場の拡大にさらに貢献しています。公衆衛生キャンペーンは、この病気と利用可能な治療法についてリスクの高い人々を教育することにますます重点を置くようになっています。技術革新により、市場は大きく変化しました。治癒率95％以上を達成し、治療期間を短縮し、副作用を最小限に抑える直接作用型抗ウイルス薬（DAA）の登場がその代表例です。さらに、パンジェノタイプDAAや定量配合剤といった革新が、治療の利便性と服薬遵守率を向上させ、より広範な患者層への効果的な治療の提供を可能にしています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022～2024年）

主要企業プロファイル

Pfizer（USA）
AbbVie（USA）
Gilead Sciences（USA）
Roche（Switzerland）
Johnson and Johnson（USA）
Novo Nordisk（Denmark）
Hepion Pharmaceutical（USA）
Vir Biotechnology（USA）
Teva Pharmaceutical（Israel）
Bristol Myers Squibb（USA）
Merck（USA）
AstraZeneca（UK）
GlaxoSmithKline（UK）
Sanofi（France）

結論と提言

Product Code: SQMIG35I2434

Global Hepatitis C Drugs Market size was valued at USD 12.5 Billion in 2023 poised to grow from USD 13.02 in 2024 to USD 18.05 Billion by 2032, growing at a CAGR of 4.2% in the forecast period (2025-2032).

The global hepatitis C drugs market is experiencing dynamic growth, fueled by increased awareness, enhanced diagnostic advancements, and effective treatment options. The rising prevalence of hepatitis C infections is propelling demand for antiviral therapies, especially among demographics with higher infection rates, such as the elderly. Efforts from governments and healthcare organizations aimed at eradicating the virus further contribute to market expansion. Public health campaigns are increasingly focusing on educating high-risk populations about the disease and available treatments. Technological advancements have transformed the market with the emergence of direct-acting antivirals (DAAs) that achieve over 95% cure rates, reduce treatment durations, and minimize side effects. Innovations like pan-genotypic DAAs and fixed-dose combinations enhance treatment convenience and compliance, ensuring broader access to effective therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hepatitis C Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hepatitis C Drugs Market Segments Analysis

The hepatitis C drugs market is segmented based on drug class, routes of administration, disease type and region. In terms of drug class, the market is segmented into direct acting antivirals (NS3/4A protease inhibitor, NS5A inhibitor, NS5B polymerase inhibitor), combination therapy, interferons, and others. Based on routes of administration, the market is segmented into oral, injectable, and others. Based on disease type, the market is bifurcated into chronic hepatitis C and acute hepatitis C. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Central & South America and the Middle East & Africa.

Driver of the Global Hepatitis C Drugs Market

The growing prevalence of hepatitis C worldwide is significantly boosting the need for effective therapies, driven by factors such as intravenous drug use and unsafe medical procedures. As more individuals are diagnosed with this viral infection, the urgency for advanced treatment solutions intensifies. Additionally, increased awareness about the disease and its potential complications further propels the market for hepatitis C medications. Healthcare providers are focusing on improving screening and treatment options, leading to a greater demand for innovative drug formulations and therapies in the market, reflecting an overarching commitment to managing and ultimately eradicating this public health concern.

Restraints in the Global Hepatitis C Drugs Market

A major challenge facing the global hepatitis C drugs market is the high cost of direct-acting antiviral (DAA) medications, which remains a hurdle for widespread treatment in regions where healthcare budgets are constrained. In many countries, limited financial resources hinder healthcare systems from providing universal access to these essential drugs, despite some efforts to lower prices through competition and government negotiations. As a result, the economic burden associated with hepatitis C treatment continues to restrict access, leaving many patients without the necessary therapies and impeding progress toward eradicating the disease on a global scale.

Market Trends of the Global Hepatitis C Drugs Market

The global Hepatitis C drugs market is witnessing a marked transition toward affordable Direct-Acting Antivirals (DAAs) and generic formulations, driven by the expiration of patents and the implementation of voluntary licensing agreements. This trend is particularly significant in low- and middle-income countries, where access to cost-effective treatment options is crucial for controlling the virus. Enhanced affordability is pivotal, aligning with the World Health Organization's goals for Hepatitis C elimination, as it fosters increased treatment rates and expands the positive impact on public health. The increased availability of generics is reshaping the competitive landscape and facilitating broader access to lifesaving therapies.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Customer Buying Behavior Analysis

Global Hepatitis C Drugs Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Direct Acting Antiviral
- NS3/4A Protease Inhibitor
- NS5A Inhibitor
- NS5B Polymerase Inhibitor
Combination Therapy
Interferons
Others

Global Hepatitis C Drugs Market Size by Routes of Administration & CAGR (2025-2032)

Market Overview
Oral
Injectable
Others

Global Hepatitis C Drugs Market Size by Disease Type & CAGR (2025-2032)

Market Overview
Chronic Hepatitis C
Acute Hepatitis C

Global Hepatitis C Drugs Market Size & CAGR (2025-2032)

North America (Drug Class, Routes of Administration, Disease Type)
- US
- Canada
Europe (Drug Class, Routes of Administration, Disease Type)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Routes of Administration, Disease Type)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Routes of Administration, Disease Type)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Routes of Administration, Disease Type)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Pfizer (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson and Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hepion Pharmaceutical (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vir Biotechnology (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

C型肝炎治療薬の市場規模、シェア、成長分析：薬剤クラス別、投与経路別、疾患タイプ別、地域別 - 産業予測、2025～2032年

Hepatitis C Drugs Market Size, Share, and Growth Analysis, By Drug Class (direct acting antiviral (NS3/4A protease inhibitor, NS5A inhibitor)), By Routes of Administration (oral, injectable), By Disease Type, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と展望

主な市場の考察

C型肝炎治療薬の市場規模：薬剤クラス別、CAGR（2025～2032年）

C型肝炎治療薬の市場規模：投与経路別、CAGR（2025～2032年）

C型肝炎治療薬の市場規模：疾患タイプ別、CAGR（2025～2032年）

C型肝炎治療薬の市場規模：地域別、CAGR（2025～2032年）